Influence of oxidation polymorphism on phenformin kinetics and dynamics

Area of Science:

• Pharmacokinetics
• Metabolism
• Clinical Pharmacology

Background:

• Phenformin, an antidiabetic drug, has been associated with lactic acidosis.
• Individual variability in drug response suggests underlying metabolic differences.

Purpose of the Study:

• To investigate the pharmacokinetic and metabolic differences of phenformin in relation to debrisoquin oxidation phenotype.
• To explore the potential link between phenformin metabolism and lactic acidosis risk.

Main Methods:

• A single 50-mg dose of phenformin was administered to eight subjects (four poor metabolizers [PM] and four extensive metabolizers [EM] of debrisoquin).
• Plasma and urinary kinetics of phenformin and its metabolite 4-hydroxy-phenformin were analyzed.
• Blood lactate, pyruvate, and glucose levels were monitored post-dosing.

Main Results:

• Poor metabolizers (PM) exhibited significantly higher peak plasma concentrations and area under the curve (AUC) for phenformin compared to extensive metabolizers (EM).
• Urinary excretion of unchanged phenformin was greater in PM, while 4-hydroxy-phenformin was detected in EM but not in most PM samples.
• Blood lactate concentrations increased markedly in PM, whereas they decreased in EM after phenformin administration.

Conclusions:

• Debrisoquin oxidation phenotype influences phenformin pharmacokinetics and metabolism.
• The impaired metabolism in PM may contribute to elevated phenformin levels and increased risk of lactic acidosis.
• These findings provide insights into the mechanisms underlying phenformin-induced lactic acidosis, even in the absence of other predisposing factors.